Source: International Congress 2018 – Pleural disease: diagnosis, monitoring and management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tsim (Glasgow, United Kingdom), C. Kelly (Glasgow, United Kingdom), L. Alexander (Glasgow, United Kingdom), A. Shaw (Glasgow, United Kingdom), J. Paul (Glasgow, United Kingdom), R. Woodward (Glasgow, United Kingdom), J. Foster (Glasgow, United Kingdom), K. Blyth (Glasgow, United Kingdom). The DIAPHRAGM study: Diagnostic and prognostic biomarkers in the rational assessment of Mesothelioma. 493

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis Source: ERJ Open Res, 7 (1) 00663-2020; 10.1183/23120541.00663-2020 Year: 2021 Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis Source: Eur Respir Rev, 30 (162) 210057; 10.1183/16000617.0057-2021 Year: 2021 Non invasive biomarkers in the diagnostic and prognostic evaluation of Pulmonary Fibrosis Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar Year: 2010 Thoracoscopy: Diagnostic and therapeutic applications Source: International Congress 2015 – Interventional pulmonology for pleural diseases Year: 2015 Late Breaking Abstract - Prognostic and therapeutic markers of malignant pleural effusion – The PROMISE study Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017 Diagnostic yield of combined epidemiological and radiological data in Malignant Pleural Mesothelioma: A Pilot Study Source: International Congress 2019 – Indoor and outdoor air quality considerations Year: 2019 Thymic tumours: Diagnostic and therapeutic approach Source: Annual Congress 2012 - Mediastinum and tracheobronchial tree Year: 2012 Clinical prognostic tools and their use in COPD. Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Diagnostic and prognostic utility of eosinophilic pleural effusions(PE) Source: Eur Respir J 2002; 20: Suppl. 38, 440s Year: 2002 Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up Source: International Congress 2014 – Markers Year: 2014 Biomarkers for clinical management Source: International Congress 2017 – PG12 Life-threatening pulmonary infections Year: 2017 Late Breaking Abstract - A symptom-based algorithm to improve asthma diagnosis in early childhood:the CHILD Cohort Study Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019 Sarcoidosis: Clinical course and prognostic predictors Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases Year: 2010 Prognostic value of symptoms at lung cancer diagnosis: a two-year observational study Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Diagnostic markers of lung cancer in bronquial fluid: Development of inmunoassays and validation Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Streamlining diagnostic work-up of pulmonary embolism: Comparing YEARS algorithm with original and simplified Well’s scores Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Prognostic indices for COPD patient management: how many do we need? Source: Eur Respir J 2011; 39: 223-224 Year: 2012 Prognostic indices for COPD patient management: how many do we need? Source: Eur Respir J 2012; 39: 223-224 Year: 2012 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012